BRPI0513379A - derivados de sulfonamida - Google Patents
derivados de sulfonamidaInfo
- Publication number
- BRPI0513379A BRPI0513379A BRPI0513379-3A BRPI0513379A BRPI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A
- Authority
- BR
- Brazil
- Prior art keywords
- sulfonamide derivatives
- racemates
- alzheimer
- disease
- compounds
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
DERIVADOS DE SULFONAMIDA. A invenção refere-se a Compostos da fórmula geral (I), em que R¬ 1¬-R¬ 5¬ e R¬ 2¬-R¬ 4¬ são como descrito nas reivindicações e a sais de adição de ácido farmaceuticamente adequados, enantiómeros puros óticos, racematos ou misturas diastereoméricas destes para o tratamento de doença de Alzheimer ou cânceres comuns.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103339 | 2004-07-13 | ||
| PCT/EP2005/007268 WO2006005486A1 (en) | 2004-07-13 | 2005-07-06 | Sulfonamide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513379A true BRPI0513379A (pt) | 2008-05-06 |
Family
ID=34971295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513379-3A BRPI0513379A (pt) | 2004-07-13 | 2005-07-06 | derivados de sulfonamida |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7253158B2 (pt) |
| EP (1) | EP1768960A1 (pt) |
| JP (1) | JP4845883B2 (pt) |
| KR (1) | KR100880972B1 (pt) |
| CN (2) | CN101035765B (pt) |
| AU (1) | AU2005261932B2 (pt) |
| BR (1) | BRPI0513379A (pt) |
| CA (1) | CA2573372A1 (pt) |
| MX (1) | MX2007000468A (pt) |
| RU (1) | RU2378258C2 (pt) |
| WO (1) | WO2006005486A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2325205T3 (es) | 2001-12-20 | 2009-08-28 | Bristol-Myers Squibb Company | Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides. |
| US7569562B2 (en) | 2005-01-18 | 2009-08-04 | Elan Pharmaceuticals, Inc. | N-substituted heterocyclic sulfonamides |
| EP1915345B1 (en) * | 2005-08-12 | 2010-12-22 | F. Hoffmann-La Roche AG | Fluoro substituted 2-oxo azepan derivatives |
| CA2705489A1 (en) * | 2007-12-05 | 2009-06-11 | Basf Se | Pyridylmethyl-sulfonamide compounds |
| US8457989B2 (en) * | 2009-01-09 | 2013-06-04 | Cerner Innovation, Inc. | Direct reporting of adverse events |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) * | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| GB201009603D0 (en) * | 2010-06-08 | 2010-07-21 | Cambridge Entpr Ltd | Anti-inflammatory agent |
| WO2012014127A1 (en) * | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| CN102718711A (zh) * | 2011-03-30 | 2012-10-10 | 北京德众万全医药科技有限公司 | 一种制备(R)-α-氨基己内酰胺盐酸盐的新方法 |
| CN102911118B (zh) * | 2012-11-09 | 2014-04-09 | 天津商业大学 | 一类苯并氮杂卓类衍生物及其制备方法和用途 |
| CN103073498A (zh) * | 2012-12-21 | 2013-05-01 | 北京万全德众医药生物技术有限公司 | (R)-α-氨基己内酰胺的制备新方法 |
| US20150141433A1 (en) * | 2013-09-26 | 2015-05-21 | Mnemosyne Pharmaceuticals, Inc. | N-arylmethyl sulfonamide negative modulators of nr2a |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
| CN110337291A (zh) | 2016-12-16 | 2019-10-15 | 帕珀莱恩医疗公司 | 治疗耳蜗突触病变的方法 |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| CA3108519A1 (en) | 2018-08-03 | 2020-04-30 | Cadent Therapeutics, Inc. | Heteroaromatic nmda receptor modulators and uses thereof |
| CN109320456A (zh) * | 2018-11-16 | 2019-02-12 | 天津商业大学 | 新晶型的抗肿瘤化合物及其制备方法和含其的组合物 |
| CN118994009A (zh) * | 2023-05-19 | 2024-11-22 | 中国石油化工股份有限公司 | 单苯甲基氨基己内酰胺的制备方法及其应用、功能性尼龙-6 |
| CN117447298A (zh) * | 2023-08-29 | 2024-01-26 | 上海泰坦科技股份有限公司 | 一种卤代甲基二氟甲基苯的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1593888A (en) * | 1977-12-22 | 1981-07-22 | Wyeth John & Brother Ltd | Hexahydroazepine piperidine and pyrrolidine derivatives |
| US6107291A (en) * | 1997-12-19 | 2000-08-22 | Amgen Inc. | Azepine or larger medium ring derivatives and methods of use |
| EP1268434A1 (en) * | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
| TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| EP1636196A1 (en) * | 2003-03-14 | 2006-03-22 | AstraZeneca AB | Novel lactams and uses thereof |
| CA2544350A1 (en) * | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
-
2005
- 2005-07-06 AU AU2005261932A patent/AU2005261932B2/en not_active Ceased
- 2005-07-06 WO PCT/EP2005/007268 patent/WO2006005486A1/en not_active Ceased
- 2005-07-06 MX MX2007000468A patent/MX2007000468A/es active IP Right Grant
- 2005-07-06 JP JP2007520712A patent/JP4845883B2/ja not_active Expired - Fee Related
- 2005-07-06 EP EP05754795A patent/EP1768960A1/en not_active Withdrawn
- 2005-07-06 CA CA002573372A patent/CA2573372A1/en not_active Abandoned
- 2005-07-06 RU RU2007100229/04A patent/RU2378258C2/ru not_active IP Right Cessation
- 2005-07-06 CN CN2005800237016A patent/CN101035765B/zh not_active Expired - Fee Related
- 2005-07-06 BR BRPI0513379-3A patent/BRPI0513379A/pt not_active IP Right Cessation
- 2005-07-06 CN CN200910253194A patent/CN101747324A/zh active Pending
- 2005-07-06 KR KR1020077000740A patent/KR100880972B1/ko not_active Expired - Fee Related
- 2005-07-12 US US11/179,703 patent/US7253158B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007100229A (ru) | 2008-08-20 |
| CN101747324A (zh) | 2010-06-23 |
| JP2008505948A (ja) | 2008-02-28 |
| US7253158B2 (en) | 2007-08-07 |
| AU2005261932B2 (en) | 2011-10-13 |
| WO2006005486A1 (en) | 2006-01-19 |
| US20060014945A1 (en) | 2006-01-19 |
| CN101035765B (zh) | 2010-10-13 |
| CN101035765A (zh) | 2007-09-12 |
| EP1768960A1 (en) | 2007-04-04 |
| KR100880972B1 (ko) | 2009-02-03 |
| MX2007000468A (es) | 2007-03-08 |
| RU2378258C2 (ru) | 2010-01-10 |
| KR20070026799A (ko) | 2007-03-08 |
| CA2573372A1 (en) | 2006-01-19 |
| JP4845883B2 (ja) | 2011-12-28 |
| AU2005261932A1 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
| DK1689721T3 (da) | Aminopyrazolderivater som GSK-3-ihibitorer | |
| IS2696B (is) | Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð | |
| BRPI0410760A (pt) | compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos | |
| BRPI0515577A (pt) | compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação | |
| BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| BR0214386A (pt) | Método para identificação de enzimas de objetivação a tumor | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| BRPI0519243A2 (pt) | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
| BR0210384A (pt) | Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença | |
| BRPI0911035B8 (pt) | ativadores de pirrolidinona glicoquinase | |
| BRPI0413245A (pt) | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos | |
| NO20075111L (no) | Farmasoytisk sammensetning | |
| EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
| DK1789398T3 (da) | 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE) | |
| BRPI0411891A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3 | |
| SE0401970D0 (sv) | Novel compounds | |
| BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
| NO20050088L (no) | Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav | |
| DK1670903T3 (da) | Behandling af neurodegenerative sygdomme | |
| BRPI0511874A (pt) | derivados da pirrolopiridina | |
| BRPI0411122A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores gsk-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |